Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Jason J. Luke, Manish R. Patel, Erika Paige Hamilton, Bartosz Chmielowski, Susanna Varkey Ulahannan, Hedy L. Kindler, Shakeela Wazeen Bahadur, Philip R. Clingan, Girish Mallesara, Andrew James Weickhardt, Scott Currence, Linzhi Xu, Sanjeev Kaul, Francine Chen, Paul A. Moore, Ezio Bonvini, Brad Sumrow, George Blumenschein
Title A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD‑1 and LAG‑3, in patients with unresectable or metastatic neoplasms.
Journal
Vol
Issue
Date
URL https://meetinglibrary.asco.org/record/185039/abstract
Abstract Text J Clin Oncol 38: 2020 (suppl; abstr 3004), DOI: 10.1200/JCO.2020.38.15_suppl.3004

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown stomach cancer not applicable MGD013 Case Reports/Case Series Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in a patient with gastric cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown Advanced Solid Tumor not applicable MGD013 Phase I Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in 7.3% (3/41) and stable disease in 51.2% (21/41) of response-evaluable patients with advanced solid tumors in the dose escalation cohort (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown malignant mesothelioma not applicable MGD013 Case Reports/Case Series Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in a patient with mesothelioma (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
ERBB2 positive Advanced Solid Tumor predicted - sensitive Margetuximab + MGD013 Phase I Actionable In a Phase I trial, MGD013 and Margetuximab (MGAH22) combination treatment resulted in a partial response in 50% (3/6) and stable disease in 33.3% (2/6) of patients with ERBB2 (HER2)-positive advanced solid tumors (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Margetuximab + MGD013 Case Reports/Case Series Actionable In a Phase I trial, MGD013 and Margetuximab (MGAH22) combination treatment resulted in a partial response in 2 patients with ERBB2 (HER2)-positive breast cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
ERBB2 positive colorectal cancer predicted - sensitive Margetuximab + MGD013 Case Reports/Case Series Actionable In a Phase I trial, MGD013 and Margetuximab (MGAH22) combination treatment resulted in a partial response in a patient with ERBB2 (HER2)-positive colorectal cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown ovary epithelial cancer not applicable MGD013 Phase I Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in 13.3% and stable disease in 46.7% (7/15) of patients with epithelial ovarian cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...
Unknown unknown triple-receptor negative breast cancer not applicable MGD013 Phase I Actionable In a Phase I trial, MGD013 treatment resulted in a partial response in 14.3% (2/14) and stable disease in 35.7% (5/14) of patients with triple-receptor negative breast cancer (J Clin Oncol 38: 2020 (suppl; abstr 3004); NCT03219268). detail...